# Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

> **NCT07186621** · PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 286 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Radiotherapy, Adjuvant
- Immune Checkpoint Inhibitor
- TACE
- Narrow Margin

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** radiotherapy
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT07186621
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2027-07-09
- **Final completion:** 2028-11-30
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07186621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07186621, "Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07186621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*